Real-world comparison of first-line antiseizure monotherapy and the role of age at treatment initiation in newly diagnosed childhood epilepsy: A cohort study from a tertiary center.

ABSTRACT:

Objective

This study was undertaken to evaluate the real-world effectiveness and tolerability of first-line antiseizure medication (ASM) monotherapy in children with newly diagnosed epilepsy, focusing on comparative outcomes across developmental age groups and ASM types, and identifying clinical risk factors of treatment failure.

Methods

This retrospective cohort study analyzed 10 years of electronic medical records from Shenzhen Children's Hospital. Children aged ≤18 years who initiated monotherapy with one of five ASMs (oxcarbazepine, valproate, levetiracetam, topiramate, or lamotrigine) were included. The primary outcome was treatment success, defined as sustained seizure and side effect freedom at the defined analytic endpoint. Outcomes based on the 2010 International Le

SUBMITTER: Li N 

PROVIDER: S-EPMC12779321 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature